Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022

IMPORTANCE: Adjuvant therapies are often approved based on improvements in disease-, progression-, or relapse-free survival (ie, an event). An important estimate in adjuvant therapies is the cost per event averted. OBJECTIVE: To characterize the costs per event averted of anticancer drugs approved b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousavi, Idine, Olivier, Timothée, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187950/
https://www.ncbi.nlm.nih.gov/pubmed/35687338
http://dx.doi.org/10.1001/jamanetworkopen.2022.16058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187950/
https://www.ncbi.nlm.nih.gov/pubmed/35687338
http://dx.doi.org/10.1001/jamanetworkopen.2022.16058

Ejemplares similares